J. Bennet

发表

Response after One Dose of a Monovalent Influenza A (H1N1) 2009 Vaccine — Preliminary Report

C. Wichems, M. Greenberg, G. Hartel, 2009 .

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

D. Purcell, K. Subbarao, Thi H. O. Nguyen, 2021, The Lancet Infectious Diseases.

Safety and immunogenicity of an inactivated thimerosal‐free influenza vaccine in infants and children

J. McVernon, P. Richmond, T. Nolan, 2009, Influenza and other respiratory viruses.

Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine.

T. Cate, W. Keitel, K. Edwards, 2008, Vaccine.

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

M. Zambon, P. Richmond, T. Nolan, 2008, Vaccine.

Issues about pertussis vaccines

I. Gust, J. Bennet, S. Hurley, 1998, The Lancet.

Response to a monovalent 2009 influenza A (H1N1) vaccine.

C. Wichems, M. Greenberg, G. Hartel, 2009, The New England journal of medicine.

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.

J. McVernon, M. Zambon, P. Richmond, 2008, Vaccine.

Negative staining can cause clumping of Bordetella pertussis fimbriae.

E. Pietrzykowski, A. Stefancic, D. Drane, 1994, Micron.

Response to a monovalent 2009 influenza A (H1N1) vaccine.

M. Greenberg, G. Hartel, R. Basser, 2009, The New England journal of medicine.